作者
Michael J Joyner, Rickey E Carter, Jonathon W Senefeld, Stephen A Klassen, John R Mills, Patrick W Johnson, Elitza S Theel, Chad C Wiggins, Katelyn A Bruno, Allan M Klompas, Elizabeth R Lesser, Katie L Kunze, Matthew A Sexton, Juan C Diaz Soto, Sarah E Baker, John RA Shepherd, Noud van Helmond, Nicole C Verdun, Peter Marks, Camille M van Buskirk, Jeffrey L Winters, James R Stubbs, Robert F Rea, David O Hodge, Vitaly Herasevich, Emily R Whelan, Andrew J Clayburn, Kathryn F Larson, Juan G Ripoll, Kylie J Andersen, Matthew R Buras, Matthew NP Vogt, Joshua J Dennis, Riley J Regimbal, Philippe R Bauer, Janis E Blair, Nigel S Paneth, DeLisa Fairweather, R Scott Wright, Arturo Casadevall
发表日期
2021/3/18
期刊
New England Journal of Medicine
卷号
384
期号
11
页码范围
1015-1027
出版商
Massachusetts Medical Society
简介
Background
Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be passively transferred to the plasma recipient. Whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death is unknown.
Methods
In a retrospective study based on a U.S. national registry, we determined the anti–SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19. The primary outcome was death within 30 days after plasma transfusion. Patients who were enrolled through July 4, 2020, and for whom data on anti–SARS-CoV-2 antibody levels in plasma transfusions and on 30-day mortality were available were included in the analysis …
学术搜索中的文章
MJ Joyner, RE Carter, JW Senefeld, SA Klassen… - New England Journal of Medicine, 2021